文献速递神经免疫

芬戈莫德对多发性硬化患者灰质、丘脑和白质的影响

Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.
PubMed 文献 · Neurology · 2018-03-14

汇总两项III期研究共2064例复发缓解型多发性硬化患者,比较芬戈莫德0.5mg、1.25mg与安慰剂对深部灰质、丘脑、皮质灰质、白质和脑室体积的影响。芬戈莫德显著减少深部灰质和丘脑体积损失,白质丢失和脑室扩大也显著少于安慰剂,但皮质灰质体积损失减少不显著。作者认为减少深部灰质和丘脑体积损失可能改善长期结局。

要点

  • 芬戈莫德0.5mg和1.25mg较安慰剂显著减少深部灰质体积损失。
  • 芬戈莫德较安慰剂显著减少丘脑体积损失。
  • 芬戈莫德对皮质灰质体积损失减少不显著。

核心结论

  • 芬戈莫德较安慰剂显著减少复发缓解型多发性硬化患者的深部灰质体积损失(包括丘脑)。
  • 作者认为减少深部灰质和丘脑体积损失可能改善长期结局。

研究设计与样本

  • 汇总两项III期研究数据,共2064/2355例(88%)纳入分析:芬戈莫德0.5mg组783例、芬戈莫德1.25mg组799例、安慰剂组773例。
  • 采用FMRIB整合配准与分割工具评估深部灰质和丘脑体积自基线的百分比变化,采用SIENAX评估白质、皮质灰质和脑室体积,评估时间点为第12个月和第24个月。

主要发现

  • 基线时复合脑体积(BVz=皮质灰质+深部灰质+白质)与SIENAX标准化脑体积相关(r=0.938,p<0.001);2年内BVz自基线百分比变化与SIENAX百分比脑体积变化相关(r=0.713,p<0.001)。
  • 安慰剂组体积减少以皮质灰质最明显,相对变化以深部灰质最强。
  • 24个月内芬戈莫德较安慰剂显著减少深部灰质体积损失(0.5mg -14.5%,p=0.017;1.25mg -26.6%,p<0.01)和丘脑体积损失(0.5mg -26.1%,p=0.006;1.25mg -49.7%,p<0.001)。
  • 芬戈莫德较安慰剂显著减少白质丢失和脑室扩大(均p<0.001);皮质灰质体积损失减少不显著。
  • 基线高T2病灶体积预测研究期间皮质灰质、深部灰质和丘脑体积损失(p<0.0001),但不预测白质丢失。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the effect of fingolimod on deep gray matter (dGM), thalamus, cortical GM (cGM), white matter (WM), and ventricular volume (VV) in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: Data were pooled from 2 phase III studies. A total of 2,064 of 2,355 (88%) contributed to the analysis: fingolimod 0.5 mg n = 783, fingolimod 1.25 mg n = 799, or placebo n = 773. Percentage change from baseline in dGM and thalamic volumes was evaluated with FMRIB's Integrated Registration & Segmentation Tool; WM, cGM, and VV were evaluated with structural image evaluation using normalization of atrophy cross-sectional version (SIENAX) at months 12 and 24. RESULTS: At baseline, compound brain volume (brain volume in the z block [BVz] = cGM + dGM + WM) correlated with SIENAX-normalized brain volume (r = 0.938, p < 0.001); percentage change from baseline in BVz over 2 years correlated with structural image evaluation using normalization of atrophy percentage brain volume change (r = 0.713, p < 0.001). For placebo, volume reductions were most pronounced in cGM, and relative changes from baseline were strongest in dGM. Over 24 months, there were significant reductions with fingolimod vs placebo for dGM (0.5 mg -14.5%, p = 0.017; 1.25 mg -26.6%, p < 0.01) and thalamus (0.5 mg -26.1%, p = 0.006; 1.25 mg -49.7%, p < 0.001). Reduction of cGM volume loss was not significant. Significantly less WM loss and VV enlargement were seen with fingolimod vs placebo (all p < 0.001). A high T2 lesion volume at baseline predicted on-study cGM, dGM, and thalamic volume loss (p < 0.0001) but not WM loss. Patients taking placebo with high dGM (hazard ratio [HR] 0.54, p = 0.0323) or thalamic (HR 0.58, p = 0.0663) volume at baseline were less likely to show future disability worsening. CONCLUSIONS: Fingolimod significantly reduced dGM volume loss (including thalamus) vs placebo in patients with RRMS. Reducing dGM and thalamic volume loss might improve long-term outcome.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Gaetano L, Häring DA, Radue EW, et al. Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis. Neurology. 2018. PMID: 29540589. doi:10.1212/WNL.0000000000005292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。